Sodium butyrate has anti-proliferative, pro-differentiating, and immunomodulatory effects in osteosarcoma cells and counteracts the TNFα-induced low-grade inflammation

International Journal of Immunopathology and Pharmacology

Volumn 32, Issue , 2018, Pages

  Perego, Silvia ^a   Sansoni, Veronica ^a   Banfi, Giuseppe ^a,b   Lombardi, Giovanni ^a  

^a IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Cytokines; Histone deacetylases; NF B activation; Osteosarcoma cells; Sodium butyrate

Indexed keywords

ALKALINE PHOSPHATASE; BUTYRIC ACID; COL1A1 PROTEIN; DNA; HISTONE DEACETYLASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; PROTEIN; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL LYSATE; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA CONTENT; DRUG MEGADOSE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; OSTEOSARCOMA CELL; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; CELL SURVIVAL; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECT; IMMUNOLOGY; METABOLISM; OSTEOSARCOMA; PHYSIOLOGY; TUMOR CELL LINE;

BUTYRIC ACID; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; OSTEOSARCOMA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85041369058     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/0394632017752240     Document Type: Article

References (45)

1. Bach Knudsen KE, Serena A, Canibe N, et al. (2003) New insight into butyrate metabolism. Proceedings of the Nutrition Society 62: 81-86.
2. Israel M and Schwartz L (2011) The metabolic advantage of tumor cells. Molecular Cancer 10: 70.
3. Goncalves P and Martel F (2013) Butyrate and colorectal cancer: The role of butyrate transport. Current Drug Metabolism 14: 994-1008.
4. Bultman SJ (2014) Molecular pathways: Geneenvironment interactions regulating dietary fiber induction of proliferation and apoptosis via butyrate for cancer prevention. Clinical Cancer Research 20: 799-803.
5. Pajak B, Orzechowski A and Gajkowska B (2007) Molecular basis of sodium butyrate-dependent proapoptotic activity in cancer cells. Advances in Medical Sciences 52: 83-88.
6. Brand-Miller JC (2003) Glycemic load and chronic disease. Nutrition Reviews 61: S49-S55.
7. Davie JR (2003) Inhibition of histone deacetylase activity by butyrate. Journal of Nutrition 133: 2485S-2493S.
8. Donohoe DR, Collins LB, Wali A, et al. (2012) The Warburg effect dictates the mechanism of butyratemediated histone acetylation and cell proliferation. Molecular Cell 48: 612-626.
9. Vinolo MA, Rodrigues HG, Nachbar RT, et al. (2011) Regulation of inflammation by short chain fatty acids. Nutrients 3: 858-876.
10. Katono T, Kawato T, Tanabe N, et al. (2008) Sodium butyrate stimulates mineralized nodule formation and osteoprotegerin expression by human osteoblasts. Archives of Oral Biology 53: 903-909.
11. Lamour V, Detry C, Sanchez C, et al. (2007) RUNX2-and histone deacetylase 3-mediated repression is relieved in differentiating human osteoblast cells to allow high bone sialoprotein expression. Journal of Biological Chemistry 282: 36240-36249.
12. Lombardi G, Perego S, Luzi L, et al. (2015) A fourseason molecule: Osteocalcin. Updates in its physiological roles. Endocrine 48: 394-404.
13. Xie C, Wu B, Chen B, et al. (2016) Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2-p53 signaling. Oncotargets and Therapy 9: 4005-4013.
14. Czekanska EM, Stoddart MJ, Richards RG, et al. (2012) In search of an osteoblast cell model for in vitro research. European Cells & Materials 24: 1-17.
15. Kansara M, Teng MW, Smyth MJ, et al. (2014) Translational biology of osteosarcoma. Nature Reviews Cancer 14: 722-735.
16. Van Driel M and van Leeuwen JP (2014) Cancer and bone: A complex complex. Archives of Biochemistry and Biophysics 561: 159-166.
17. Abu-Amer Y (2009) Inflammation, cancer, and bone loss. Current Opinion in Pharmacology 9: 427-433.
18. Czekanska EM, Stoddart MJ, Ralphs JR, et al. (2014) A phenotypic comparison of osteoblast cell lines versus human primary osteoblasts for biomaterials testing. Journal of Biomedical Materials Research Part A 102: 2636-2643.
19. McAllister SS and Weinberg RA (2014) The tumourinduced systemic environment as a critical regulator of cancer progression and metastasis. Nature Cell Biology 16: 717-727.
20. Kahles F, Findeisen HM and Bruemmer D (2014) Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes. Molecular Metabolism 3: 384-393.
21. Arjomandi M, Frelinger J, Donde A, et al. (2011) Secreted osteopontin is highly polymerized in human airways and fragmented in asthmatic airway secretions. PLoS ONE 6: e25678.
22. Nishimichi N, Hayashita-Kinoh H, Chen C, et al. (2011) Osteopontin undergoes polymerization in vivo and gains chemotactic activity for neutrophils mediated by integrin alpha9beta1. Journal of Biological Chemistry 286: 11170-11178.
23. Morozumi A (2011) High concentration of sodium butyrate suppresses osteoblastic differentiation and mineralized nodule formation in ROS17/2.8 cells. Journal of Oral Science 53: 509-516.
24. Yang L, Li Z, Li X, et al. (2010) Butyric acid stimulates bone sialoprotein gene transcription. Journal of Oral Science 52: 231-237.
25. Lee HW, Suh JH, Kim AY, et al. (2006) Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Molecular Endocrinology 20: 2432-2443.
26. Schroeder TM and Westendorf JJ (2005) Histone deacetylase inhibitors promote osteoblast maturation. Journal of Bone and Mineral Research 20: 2254-2263.
27. Iwamoto M, Friedman EJ, Sandhu P, et al. (2013) Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemotherapy and Pharmacology 72: 493-508.
28. Andela VB, Sheu TJ, Puzas EJ, et al. (2002) Malignant reversion of a human osteosarcoma cell line, SaOS-2, by inhibition of NFkappaB. Biochemical and Biophysical Research Communications 297: 237-241.
29. Lu J, Song G, Tang Q, et al. (2015) IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-kappaB signaling. Journal of Clinical Investigation 125: 1839-1856.
30. Mori K, Le Goff B, Berreur M, et al. (2007) Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. Journal of Pathology 211: 555-562.
31. Endo-Munoz L, Evdokiou A and Saunders NA (2012) The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. Biochimica Et Biophysica Acta 1826: 434-442.
32. Buenrostro D, Mulcrone PL, Owens P, et al. (2016) The bone microenvironment: A fertile soil for tumor growth. Current Osteoporosis Reports 14: 151-158.
33. Theoleyre S, Wittrant Y, Tat SK, et al. (2004) The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodeling. Cytokine & Growth Factor Reviews 15: 457-475.
34. Mori K, Ando K, Heymann D, et al. (2009) Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells? Histology and Histopathology 24: 235-242.
35. Lamoureux F, Richard P, Wittrant Y, et al. (2007) Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: Blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Research 67: 7308-7318.
36. Kitazawa S and Kitazawa R (2002) RANK ligand is a prerequisite for cancer-associated osteolytic lesions. Journal of Pathology 198: 228-236.
37. Grimaud E, Soubigou L, Couillaud S, et al. (2003) Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. American Journal of Pathology 163: 2021-2031.
38. Lombardi G, Sanchis-Gomar F, Perego S, et al. (2016) Implications of exercise-induced adipo-myokines in bone metabolism. Endocrine 54: 284-305.
39. Ohlsson C and Sjogren K (2017) Osteomicrobiology: A new cross-disciplinary research field. Calcified Tissue International. Epub ahead of print 27 October 2017. DOI: 10.1007/s00223-017-0336-6.
40. Huynh NC, Everts V and Ampornaramveth RS (2017) Histone deacetylases and their roles in mineralized tissue regeneration. Bone Reports 7: 33-40.
41. Quivy V and Van Lint C (2004) Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. Biochemical Pharmacology 68(6): 1221-1229.
42. Ammendola S, Loreto MD and d’Abusco AS (2017) Modulatory effects of a nutraceutical supplement on SaOS-2 cells reveal its phlebotonic activity. Journal of American College of Nutrition 36(4): 268-272.
43. Ghali O, Chauveau C, Lencel P, et al. (2010) RUNX2 regulates the effects of TNFα on proliferation and apoptosis in SaOS-2 cells. Bone 46: 901-910.
44. Frost A, Jonsson KB, Nilsson O, et al. (1997) Inflammatory cytokines regulate proliferation of cultured human osteoblasts. Acta Orthopaedica Scandinavica 68(2): 91-96.
45. Daniele S, Natali L, Giacomelli C, et al. (2017) Osteogenesis is improved by low tumor necrosis factor alpha concentration through the modulation of Gs-coupled receptor signals. Molecular Cell Biology 37(8): e00442-16.